Status: Recruiting
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Participants needed: 30
Trial details
Phase: Phase 3Age: 12-85Biological sex: AllType: InterventionalSponsor: Annexon, Inc.Updated: May 28, 2026Locations: 13
Eligibility criteria
Diagnosis of GBS according to the National Institute of Neurological Disorders a... [+2]
Previous or intended treatment with either plasma exchange or IV immunoglobulin... [+1]